Clinical trial
Prophylactic Minimally-invasive Local Ablation Therapies for the Hepatic Dysplastic Nodules in Patients With Positive Hepatitis B Surface Antigen (HBsAg).
NCT02793791 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prophylactic Minimally-invasive Local Ablation Therapies for the Hepatic Dysplastic Nodules in Patients With Positive Hepatitis B Surface Antigen (HBsAg).
- Lead sponsor
- Shandong Cancer Hospital and Institute
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- September 30, 2016
- Completion date
- December 31, 2022
- Enrollment
- 30 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
chronic hepatitis b, dysplastic nodule of liver